查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198769

關節內置換療法市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Viscosupplementation Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內 (2023-2028)，關節內置換療法市場預計將以 5.8% 的複合年增長率增長。

COVID-19 大流行的出現影響了關節內置換療法市場，因為世界各國政府實施的封鎖限制導致醫院和門診手術中心的就診人數減少。. 由於這些限制，醫院停止了非緊急手術，影響了患者的生命。 例如，Enrico Ragni 等人在臨床藥理學和治療學雜誌上發表的一項研究 Risk 有望啟動。 因此，臨床醫生和整形外科醫生不僅應仔細檢查骨關節炎患者的症狀管理，還應仔細檢查 COVID-19 大流行期間骨關節炎治療可能導致的合併症，這需要進行評估。 由於上述因素，預計所研究的市場將在大流行期間受到影響。 然而，由於程序的重新開放、醫院就診量的增加和對 COVID-19 的放鬆管制，預計在此期間市場將獲得潛力。

推動市場增長的某些因素包括越來越多的骨關節炎患者以及越來越多地引入先進和組合產品。 例如，根據美國疾病控制與預防中心2020年4月發表的一篇題為“骨關節炎”的文章，美國約有3250萬人患有骨關節炎。 除此之外，62% 的女性患有骨關節炎。 同樣，根據國家生物技術信息中心 2021 年 1 月發表的論文《哈裡亞納邦 Ballabgarh 農村地區老年人膝骨關節炎的患病率及其決定因素及其對生活質量的影響》，64.3% 的老年人患有膝骨關節炎和患有膝關節炎的老年人的生活質量明顯較差。 此外，肥胖也是骨科疾病的危險因素。 例如，根據國家生物技術信息中心 2021 年發表的題為“Prevalence of Obesity in India and its Neurological Implications”的論文《Prevalence of Obesity in India and its Neurological Implications》。 一項全國性橫斷面研究的多因素分析”：印度的肥胖患病率為 40.3%，南印度最高，為 46.51%，東印度最高，為 32.96%。因此，骨關節炎患者的負擔增加將增加對關節內替代療法的需求，關節內替代療法通過增加關節間潤滑來減輕關節疼痛，預計將在預測期內持續。據認為，這將增加中期的市場增長。

但是，監管問題和對關節內置換療法的認識不足可能會限制市場擴張。

關節內置換療法市場趨勢

在預測期內，預計單一注入段將繼續保持較高的複合年增長率

單次注射領域對門診手術有很高的需求，重點是提高醫生和患者的便利性並提供當日手術護理，包括預防（手術）和診斷程序，骨關節炎預計在此期間將出現強勁增長以等因素，更多的公司專注於開發單針劑用於治療。

越來越多的公司專注於開發單劑量注射劑來治療骨關節炎患者。 例如，2021 年 10 月，Seikagaku 公司在台灣推出了 Hylink，一種用於治療膝骨關節炎的單次關節內註射關節內替代療法。 2020 年 9 月，Bioventus 用於治療骨關節炎 (OA) 相關疼痛的單次注射透明質酸 (HA) DUROLANE 達到了全球兩百萬次治療的裡程碑，實現了結石。 同樣，2021 年 8 月，Flexion Therapeutics, Inc. 將推出 ZILRETTA（曲安奈德緩釋單次注射劑）用於治療肩骨關節炎 (OA) 和肩關節囊粘連 (AC) 患者。 2 景天混懸液的藥代動力學（PK）研究）。

因此，上述因素預計將增加單次注射的需求，進而推動預測期內關節內替代療法市場的增長率。

預計北美將佔據較大的市場份額

由於骨關節炎和相關疾病患病率上升、老年人口不斷增加、醫療保健基礎設施發達以及對非手術程序的需求不斷增加等因素，北美將在預測期內成為世界上最大的市場。它是有望主導關節內替代療法市場。

關節炎、骨關節炎和膝關節疼痛的負擔日益加重，是推動該地區關節內置換療法市場需求的關鍵因素。 例如，根據 2021 年加拿大統計局的數據，到 2020 年，大約有 590 萬加拿大成年人患有關節炎。 關節炎的患病率隨著年齡的增長而增加，並且在女性中更高。 此外，根據美國疾病控制與預防中心 (CDC) 於 2021 年 10 月更新的數據，美國約有四分之一 (23.7%) 的成年人，即約 5850 萬人，被醫生診斷為關節炎。據說有 同樣，根據加拿大政府在 2020 年 9 月的數據，大約 374,000 名 16 歲及以上的加拿大人 (1.2%) 被診斷患有類風濕性關節炎。 因此，隨著患者關節炎和膝痛病例的增加，關節內替代療法的需求預計將增加，從而推動預測期內的市場增長率。

此外，隨著老年人口的增加，患有各種關節炎問題的人數將會增加，這將增加對非手術程序的需求，這可能會增加市場增長。 例如，根據美國健康排名2021年高級報告中公佈的數據，美國65歲及以上的成年人超過5400萬，佔總人口的16.5%，老年人口總數到 2050 年，65 歲及以上的人口預計將增長到 8570 萬，約佔總人口的 20%。

此外，越來越多的公司專注於開發關節內替代療法來治療骨關節炎和患者的關節痛，這也促進了該地區的整體市場增長。 例如，2021 年 1 月，Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare 將開發疼痛治療藥物，並在加拿大聯合推出 NeoVisc+2 mL 和 NeoVisc ONE 4 mL 以改進功能。

因此，預計在預測期內，關節炎和相關疾病負擔的增加、老年人口的增加以及產品發布的增加將推動該地區的市場增長。

關節內置換療法市場的競爭對手分析

全球關節內置換療法市場競爭激烈，主要參與者採用合作夥伴關係、產品發布、批准和協作等各種商業策略來維持其市場地位。 主要市場參與者包括 Anika Therapeutics, Inc.、Bioventus LLC、Ferring Pharmaceuticals、Fidia Farmaceutici s.p.a.、Sanofi SA、Johnson & Johnson Services, Inc.、Zimmer Biomet、Wellchem Pharmaceuticals Pte Ltd.和 OrthogenRx Inc。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 越來越多的骨關節炎患者
    • 介紹高性能產品和組合產品
  • 市場製約因素
    • 監管問題，意識低下
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 按劑量
    • 單劑量
    • 3 次注射
    • 5 次注射
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Anika Therapeutics, Inc.
    • Bioventus LLC
    • Chugai Pharmaceuticals Co., Ltd.（Roche）
    • Ferring Pharmaceuticals
    • Fidia Farmaceutici s.p.a.
    • Zimmer Biomet
    • OrthogenRx Inc.
    • Sanofi SA
    • Seikagaku Corporation
    • Aptissen
    • Johnson & Johnson Services, Inc.
    • Wellchem Pharmaceuticals Pte Ltd.

第7章 市場機會與今後動向

簡介目錄
Product Code: 69923

The viscosupplementation market is projected to grow with a CAGR of 5.8% during the forecast period (2023 - 2028).

The emergence of the COVID-19 pandemic had its impact on the viscosupplementation market due to the decline in visits to hospitals and ambulatory surgical centers because of lockdown restrictions imposed by various governments globally. Due to these restrictions, non-emergency procedures were halted in the hospitals, which have impacted the patient's life. For instance, according to a study published in the Clinical Pharmacology and Therapeutics Journal in May 2020 by Enrico Ragni et al., the presence of osteoarthritis-related concomitant disorders is expected to initiate life-threatening risks for osteoarthritis patients in the event of SARS-CoV2 viral infection. This has prompted clinicians and orthopedists to carefully check and evaluate osteoarthritis patients, not just for symptom management but also for comorbidities that may arise as a result of osteoarthritis treatment during the COVID-19 pandemic. As a result of the aforementioned factors, the market under study is projected to be impacted during the pandemic era. However, with the resumed procedures and increased hospital visits, and lessening of COVID-19 restrictions, the market is expected to gain its potential over the period.

Certain factors that are driving the market growth include the rising patient pool suffering from osteoarthritis and the increasing introduction of advanced and combination products. For instance, according to an article published by the Centers for Disease Control and Prevention in April 2020, titled "Osteoarthritis", about 32.5 million people in the United States are suffering from osteoarthritis. In addition to this, 62% of women suffer from osteoarthritis. Similarly, according to an article published by the National Center for Biotechnology Information, in January 2021, titled "Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana", it has been observed that 64.3% of the elder population is suffering from knee osteoarthritis and the elderly patients with knee osteoarthritis have considerably poorer quality-of-life. Furthermore, obesity is another risk factor contributing to orthopedic conditions. For instance, according to an article published by the National Center for Biotechnology Information, in 2021, titled "Prevalence of Obesity in India and its Neurological Implications: A Multifactor Analysis of a Nationwide Cross-Sectional Study,": the prevalence rate of obesity in India is found to be 40.3%. In addition to this, it has been that the highest rate of prevalence is found in South India with 46.51%, and the lowest in East India with 32.96%. Thus, the increasing burden of osteoarthritis in patients is likely to increase the demand for viscosupplementation procedures, which reduces the pain in joints by increasing the lubrication between them, thereby increasing the market growth over the forecast period.

However, the regulatory issues and lack of awareness regarding the viscosupplementation are likely to restrain the market expansion.

Viscosupplementation Market Trends

Single Injection Segment Expects to Register a High CAGR in the Forecast Period

The single injection segment is expected to witness significant growth over the period, owing to the factors such as providing greater physician and patient convenience, high demand for outpatient surgeries that focus on offering same-day surgical care, including preventive (surgical) and diagnostic procedures, and increasing focus of companies to develop single injection for the treatment of osteoarthritis and rising product launches.

The increasing company focuses on developing single injection products and offering treatment to patients with osteoarthritis. For instance, in October 2021, Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan. In addition, in September 2020, Bioventus reached milestones with 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). Similarly, in August 2021, Flexion Therapeutics, Inc. announced the positive results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release single injectable suspension) for the treatments of patients with shoulder osteoarthritis (OA) and adhesive capsulitis (AC) trial.

Thus, the aforementioned factors are likely to increase the demand for single injection, thereby increasing viscosupplementation market growth over the forecast period.

North America is Expected to Have the Significant Market Share

North America is expected to dominate the global viscosupplementation market over the forecast period, owing to factors such as the rising prevalence of osteoarthritis and related disorders, the rising geriatric population, well-developed healthcare infrastructure, and the increasing demand for non-surgical procedures.

The rising burden of arthritis, osteoarthritis, and knee pain is the key factor driving the demand for the viscosupplementation market in the region. For instance, according to Statistics Canada 2021, approximately 5.9 million adult Canadians had arthritis in 2020. The prevalence of arthritis increases with age and is higher among females. In addition, according to the Centers for Disease Control and Prevention (CDC) updated in October 2021, about 1 in 4 United States adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. Similarly, according to the Government of Canada in September 2020, approximately 374,000 (1.2%) Canadians aged 16 years and older live with diagnosed rheumatoid arthritis. Thus, the demand for viscosupplementation increases with the increasing cases of arthritis and knee pain in patients, which is expected to increase the market growth over the forecast period.

In addition, with an increase in the geriatric population, there is a rise in the number of people suffering from various arthritis problems which increases the demand for non-surgical procedures thereby increasing the market growth. For instance, according to the data published by America's Health Ranking in 2021 Senior Report, in the United States, there are more than 54 million adults aged 65 and older which accounts for 16.5% of the total population and the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million, accounting approximately 20% of the total population, by 2050.

Furthermore, the rising company's focus on developing viscosupplements for treating osteoarthritis and joint pain in patients is also contributing to the overall growth of the market in the region. For instance, in January 2021, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL, for the treatment of pain and improvement of joint functionality in patients affected by degenerative (age-related changes) or mechanical arthropathy (related to overuse) of the knee, in Canada.

Thus, the rising burden of arthritis and related disorders, the growing geriatric population, and increasing product launches are expected to increase the market growth in this region over the forecast period.

Viscosupplementation Market Competitor Analysis

The global viscosupplementation market is competitive with the presence of major players adopting various business strategies such as partnerships, product launches, approvals, and collaboration to withhold their market position. Some of the key market players are Anika Therapeutics, Inc., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici s.p.a., Sanofi SA, Johnson & Johnson Services, Inc., Zimmer Biomet, Wellchem Pharmaceuticals Pte Ltd., and OrthogenRx Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Patient Pool Suffering from Osteoarthritis
    • 4.2.2 Introduction of Advanced and Combination Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Issues and Lack of Awareness
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Dosage
    • 5.1.1 Single Injection
    • 5.1.2 Three Injection
    • 5.1.3 Five Injection
  • 5.2 By End-User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anika Therapeutics, Inc.
    • 6.1.2 Bioventus LLC
    • 6.1.3 Chugai Pharmaceuticals Co., Ltd. (Roche)
    • 6.1.4 Ferring Pharmaceuticals
    • 6.1.5 Fidia Farmaceutici s.p.a.
    • 6.1.6 Zimmer Biomet
    • 6.1.7 OrthogenRx Inc.
    • 6.1.8 Sanofi SA
    • 6.1.9 Seikagaku Corporation
    • 6.1.10 Aptissen
    • 6.1.11 Johnson & Johnson Services, Inc.
    • 6.1.12 Wellchem Pharmaceuticals Pte Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS